A study found unapproved formulations accounted for over 60% of psychotropic fixed dose combination drug sales in India from 2008 to 2020. The report highlights risks due to a lack of safety and efficacy evaluation, urging enhanced regulatory measures and market surveillance to mitigate potential public health threats.